Skip to main content

Conference Correspondent

Hepatotoxicity a Concern with Frontline Idelalisib
Jennifer Brown, MD, PhD, expanded upon the results of her and her colleagues’ study of the hepatotoxic effects of idelalisib, particularly as frontline treatment of younger patients with chronic lymphocytic leukemia, which was presented at the 57th American Society of Hematology Annual Meeting & Exposition. Read More ›

ASHP Foundation Forecast Provides Actionable Recommendations for Pharmacy Leaders
William A. Zellmer, BPharm, MPH, discusses how the 4th edition of the American Society of Health-System Pharmacists (ASHP) Foundation’s Pharmacy Forecast serves to improve the effectiveness of leaders in hospital and health-system pharmacy practice. Read More ›

Formulary Management and Procurement of Oncology Medications
Lindsey B. Amerine, PharmD, MS, BCPS, discussed her practice’s process for formulary management and procurement of oncology medications at the 11th annual Hematology/Oncology Pharmacy Association conference. Read More ›

Intravenous Iron Better Tolerated Than Oral Iron for Chemotherapy-Induced Anemia
Gunnar Birgegård, MD, PhD, discussed his team’s research comparing intravenous iron isomaltoside 1000 with oral iron sulphate monotherapy in patients with cancer and chemotherapy-induced anemia at the 2015 International Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Symposium on Supportive Care in Cancer. Read More ›

Developing a Pharmacist-Driven Drug-Monitoring Protocol
Felicia Zook, PharmD, BCOP, discussed her medical practice’s successful development and implementation of a pharmacist-driven drug-monitoring protocol at the 11th annual Hematology/Oncology Pharmacy Association conference. Read More ›

Meeting USP Chapter 800 Head On
Michael Koraleski, PharmD, outlined the proposed standards of the newest US Pharmacopeial Convention (USP) Chapter 800 at the 11th annual Hematology/Oncology Pharmacy As­­sociation conference. Read More ›